On September 17, AstraZeneca announced an investment of nearly 200 million yuan to fully upgrade the new drug development and supply building at the Wuxi production and supply base for the process development and production of innovative cardiovascular drugs being developed by AstraZeneca, and to support the global supply of the drug after commercialization.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.